What is the P/E ratio of WellBiotec Co 2024?
The P/E ratio cannot be calculated for WellBiotec Co at the moment.
Access the world's leading financial data and tools
Subscribe for $2 
Overview
Profile
WellBiotec Co stock stock price, forecast, news, chart, split, dividend and analysis WellBiotec Co ariva, WellBiotec Co onvista, WellBiotec Co finanzen.net, WellBiotec Co aktienfinder, WellBiotec Co marketscreener, WellBiotec Co marketwatch, WellBiotec Co bloomberg, WellBiotec Co handelsblatt, WellBiotec Co wiwo, WellBiotec Co forum
010600.KS
KR7010600005
Price
Price
545.00
Today +/-
+0
Today %
+0 %
Ticker010600.KS
ISINKR7010600005
P
WellBiotec Co stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the WellBiotec Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the WellBiotec Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the WellBiotec Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze WellBiotec Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
WellBiotec Co Stock Price History
| Date | WellBiotec Co Price |
|---|---|
| 11/14/2024 | 545.00 undefined |
| 11/13/2024 | 545.00 undefined |
| 11/12/2024 | 545.00 undefined |
| 11/11/2024 | 545.00 undefined |
| 11/8/2024 | 545.00 undefined |
| 11/7/2024 | 545.00 undefined |
| 11/6/2024 | 545.00 undefined |
| 11/5/2024 | 545.00 undefined |
| 11/4/2024 | 545.00 undefined |
| 11/1/2024 | 545.00 undefined |
| 10/31/2024 | 545.00 undefined |
| 10/30/2024 | 545.00 undefined |
| 10/29/2024 | 545.00 undefined |
| 10/28/2024 | 545.00 undefined |
| 10/25/2024 | 545.00 undefined |
| 10/24/2024 | 545.00 undefined |
| 10/23/2024 | 545.00 undefined |
| 10/22/2024 | 545.00 undefined |
| 10/21/2024 | 545.00 undefined |
WellBiotec Co Revenue, EBIT, Net Income KR7010600005 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into WellBiotec Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by WellBiotec Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects WellBiotec Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of WellBiotec Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into WellBiotec Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing WellBiotec Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on WellBiotec Co’s growth potential.
WellBiotec Co Revenue, EBIT and net profit per share
| Date | WellBiotec Co Revenue | WellBiotec Co EBIT | WellBiotec Co Net Income |
|---|---|---|---|
| 2023 | 72.13 B undefined | -15.89 B undefined | -64.98 B undefined |
| 2022 | 158.12 B undefined | 2.26 B undefined | -20.88 B undefined |
| 2021 | 108.38 B undefined | -4.32 B undefined | -33.28 B undefined |
| 2020 | 60.43 B undefined | -12.57 B undefined | -67.43 B undefined |
| 2019 | 52.33 B undefined | -6.45 B undefined | -15.3 B undefined |
| 2018 | 73.93 B undefined | -8.45 B undefined | -15.57 B undefined |
| 2017 | 70.79 B undefined | -5.13 B undefined | -8.74 B undefined |
| 2016 | 85.29 B undefined | -407 M undefined | -2.45 B undefined |
| 2015 | 112.49 B undefined | 2.08 B undefined | 550 M undefined |
| 2014 | 119.63 B undefined | 168 M undefined | -6.66 B undefined |
| 2013 | 137.76 B undefined | 1.94 B undefined | 2.37 B undefined |
| 2012 | 136.75 B undefined | 3.22 B undefined | -2.95 B undefined |
| 2011 | 119.78 B undefined | 3.68 B undefined | 1.58 B undefined |
| 2010 | 86.84 B undefined | -5.12 B undefined | -10.77 B undefined |
| 2009 | 73.92 B undefined | -1.39 B undefined | -10.71 B undefined |
| 2008 | 98.18 B undefined | -7.13 B undefined | -27.66 B undefined |
| 2007 | 112.67 B undefined | -3.92 B undefined | -6.42 B undefined |
| 2006 | 224.02 B undefined | 3.89 B undefined | 2.36 B undefined |
| 2005 | 211.66 B undefined | 4.5 B undefined | 1.14 B undefined |
| 2004 | 208.21 B undefined | 3.49 B undefined | 3.17 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 208.21 B KRW | 3.49 B KRW | 3.17 B KRW |
| 2005 | 211.66 B KRW | 4.5 B KRW | 1.14 B KRW |
| 2006 | 224.02 B KRW | 3.89 B KRW | 2.36 B KRW |
| 2007 | 112.67 B KRW | -3.92 B KRW | -6.42 B KRW |
| 2008 | 98.18 B KRW | -7.13 B KRW | -27.66 B KRW |
| 2009 | 73.92 B KRW | -1.39 B KRW | -10.71 B KRW |
| 2010 | 86.84 B KRW | -5.12 B KRW | -10.77 B KRW |
| 2011 | 119.78 B KRW | 3.68 B KRW | 1.58 B KRW |
| 2012 | 136.75 B KRW | 3.22 B KRW | -2.95 B KRW |
| 2013 | 137.76 B KRW | 1.94 B KRW | 2.37 B KRW |
| 2014 | 119.63 B KRW | 168 M KRW | -6.66 B KRW |
| 2015 | 112.49 B KRW | 2.08 B KRW | 550 M KRW |
| 2016 | 85.29 B KRW | -407 M KRW | -2.45 B KRW |
| 2017 | 70.79 B KRW | -5.13 B KRW | -8.74 B KRW |
| 2018 | 73.93 B KRW | -8.45 B KRW | -15.57 B KRW |
| 2019 | 52.33 B KRW | -6.45 B KRW | -15.3 B KRW |
| 2020 | 60.43 B KRW | -12.57 B KRW | -67.43 B KRW |
| 2021 | 108.38 B KRW | -4.32 B KRW | -33.28 B KRW |
| 2022 | 158.12 B KRW | 2.26 B KRW | -20.88 B KRW |
| 2023 | 72.13 B KRW | -15.89 B KRW | -64.98 B KRW |
WellBiotec Co Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101.45 | 98.97 | 99.06 | 120.72 | 172.36 | 181.93 | 208.21 | 211.66 | 224.02 | 112.67 | 98.18 | 73.92 | 86.84 | 119.78 | 136.75 | 137.76 | 119.63 | 112.49 | 85.29 | 70.79 | 73.93 | 52.33 | 60.43 | 108.38 | 158.12 | 72.13 |
| - | -2.45 | 0.09 | 21.87 | 42.78 | 5.55 | 14.45 | 1.66 | 5.84 | -49.70 | -12.86 | -24.71 | 17.48 | 37.94 | 14.16 | 0.74 | -13.16 | -5.97 | -24.18 | -17.01 | 4.44 | -29.21 | 15.47 | 79.34 | 45.89 | -54.38 |
| 17.51 | 17.61 | 19.15 | 17.69 | 34.08 | 37.12 | 35.43 | 37.25 | 35.42 | 6.03 | 3.97 | 14.94 | 13.29 | 11.70 | 11.01 | 9.74 | 8.16 | 9.46 | 9.26 | 3.92 | 4.55 | 16.27 | 10.60 | 8.57 | 14.05 | 13.78 |
| 17.76 | 17.43 | 18.97 | 21.36 | 58.74 | 67.52 | 73.78 | 78.84 | 79.36 | 6.79 | 3.9 | 11.05 | 11.54 | 14.01 | 15.05 | 13.42 | 9.77 | 10.64 | 7.9 | 2.78 | 3.37 | 8.51 | 6.41 | 9.29 | 22.22 | 9.94 |
| 6.19 | 4.89 | 2.27 | 2.21 | 3 | 1.3 | 3.17 | 1.14 | 2.36 | -6.42 | -27.66 | -10.71 | -10.77 | 1.58 | -2.95 | 2.37 | -6.66 | 0.55 | -2.45 | -8.74 | -15.57 | -15.3 | -67.43 | -33.28 | -20.88 | -64.98 |
| - | -20.99 | -53.60 | -2.82 | 36.24 | -56.82 | 144.33 | -64.12 | 107.39 | -372.43 | 330.64 | -61.29 | 0.57 | -114.69 | -286.22 | -180.58 | -380.33 | -108.26 | -545.45 | 256.82 | 78.06 | -1.72 | 340.78 | -50.65 | -37.26 | 211.18 |
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 3 | 7 | 10 | 11 | 12 | 13 | 14 | 15 | 15 | 15 | 20 | 42 | 44 | 55.36 | 64.32 | 79.2 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The WellBiotec Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the WellBiotec Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
WellBiotec Co stock margins KR7010600005 ·
The WellBiotec Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of WellBiotec Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for WellBiotec Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the WellBiotec Co's sales revenue. A higher gross margin percentage indicates that the WellBiotec Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the WellBiotec Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the WellBiotec Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the WellBiotec Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the WellBiotec Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the WellBiotec Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
WellBiotec Co Margin History
| WellBiotec Co Gross margin | WellBiotec Co Profit margin | WellBiotec Co EBIT margin | WellBiotec Co Profit margin |
|---|---|---|---|
| 2023 | 13.78 % | -22.03 % | -90.08 % |
| 2022 | 14.05 % | 1.43 % | -13.21 % |
| 2021 | 8.57 % | -3.99 % | -30.71 % |
| 2020 | 10.6 % | -20.8 % | -111.58 % |
| 2019 | 16.27 % | -12.32 % | -29.23 % |
| 2018 | 4.55 % | -11.43 % | -21.05 % |
| 2017 | 3.92 % | -7.25 % | -12.35 % |
| 2016 | 9.26 % | -0.48 % | -2.87 % |
| 2015 | 9.46 % | 1.85 % | 0.49 % |
| 2014 | 8.16 % | 0.14 % | -5.56 % |
| 2013 | 9.74 % | 1.41 % | 1.72 % |
| 2012 | 11.01 % | 2.35 % | -2.15 % |
| 2011 | 11.7 % | 3.08 % | 1.32 % |
| 2010 | 13.29 % | -5.9 % | -12.4 % |
| 2009 | 14.94 % | -1.88 % | -14.49 % |
| 2008 | 3.97 % | -7.26 % | -28.18 % |
| 2007 | 6.03 % | -3.48 % | -5.7 % |
| 2006 | 35.42 % | 1.74 % | 1.05 % |
| 2005 | 37.25 % | 2.13 % | 0.54 % |
| 2004 | 35.43 % | 1.68 % | 1.52 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 35.43 % | 1.68 % | 1.52 % |
| 2005 | 37.25 % | 2.13 % | 0.54 % |
| 2006 | 35.42 % | 1.74 % | 1.05 % |
| 2007 | 6.03 % | -3.48 % | -5.7 % |
| 2008 | 3.97 % | -7.26 % | -28.18 % |
| 2009 | 14.94 % | -1.88 % | -14.49 % |
| 2010 | 13.29 % | -5.9 % | -12.4 % |
| 2011 | 11.7 % | 3.08 % | 1.32 % |
| 2012 | 11.01 % | 2.35 % | -2.15 % |
| 2013 | 9.74 % | 1.41 % | 1.72 % |
| 2014 | 8.16 % | 0.14 % | -5.56 % |
| 2015 | 9.46 % | 1.85 % | 0.49 % |
| 2016 | 9.26 % | -0.48 % | -2.87 % |
| 2017 | 3.92 % | -7.25 % | -12.35 % |
| 2018 | 4.55 % | -11.43 % | -21.05 % |
| 2019 | 16.27 % | -12.32 % | -29.23 % |
| 2020 | 10.6 % | -20.8 % | -111.58 % |
| 2021 | 8.57 % | -3.99 % | -30.71 % |
| 2022 | 14.05 % | 1.43 % | -13.21 % |
| 2023 | 13.78 % | -22.03 % | -90.08 % |
WellBiotec Co Stock Sales Revenue, EBIT, Earnings per Share KR7010600005 ·
The WellBiotec Co earnings per share therefore indicates how much revenue WellBiotec Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue WellBiotec Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates WellBiotec Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of WellBiotec Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating WellBiotec Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
WellBiotec Co Revenue, EBIT and net profit per share
| Date | WellBiotec Co Sales per Share | WellBiotec Co EBIT per share | WellBiotec Co Earnings per Share |
|---|---|---|---|
| 2023 | 910.8 undefined | -200.65 undefined | -820.43 undefined |
| 2022 | 2,458.13 undefined | 35.17 undefined | -324.62 undefined |
| 2021 | 1,957.85 undefined | -78.02 undefined | -601.19 undefined |
| 2020 | 1,373.43 undefined | -285.73 undefined | -1,532.52 undefined |
| 2019 | 1,246.02 undefined | -153.48 undefined | -364.24 undefined |
| 2018 | 3,696.6 undefined | -422.55 undefined | -778.3 undefined |
| 2017 | 4,719.07 undefined | -342 undefined | -582.8 undefined |
| 2016 | 5,686.13 undefined | -27.13 undefined | -163.33 undefined |
| 2015 | 7,499.2 undefined | 138.47 undefined | 36.67 undefined |
| 2014 | 8,545 undefined | 12 undefined | -475.36 undefined |
| 2013 | 10,597.08 undefined | 149.08 undefined | 182.62 undefined |
| 2012 | 11,395.67 undefined | 268.17 undefined | -245.5 undefined |
| 2011 | 10,889.36 undefined | 334.91 undefined | 143.82 undefined |
| 2010 | 8,683.7 undefined | -512.4 undefined | -1,077 undefined |
| 2009 | 10,559.57 undefined | -198.43 undefined | -1,529.86 undefined |
| 2008 | 32,726.33 undefined | -2,375 undefined | -9,221.33 undefined |
| 2007 | 56,336 undefined | -1,959.5 undefined | -3,212 undefined |
| 2006 | 74,672.66 undefined | 1,295.67 undefined | 786 undefined |
| 2005 | 105,827.5 undefined | 2,250 undefined | 568.5 undefined |
| 2004 | 104,104.5 undefined | 1,747 undefined | 1,584.5 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2004 | 104,104.5 KRW | 1,747 KRW | 1,584.5 KRW |
| 2005 | 105,827.5 KRW | 2,250 KRW | 568.5 KRW |
| 2006 | 74,672.66 KRW | 1,295.67 KRW | 786 KRW |
| 2007 | 56,336 KRW | -1,959.5 KRW | -3,212 KRW |
| 2008 | 32,726.33 KRW | -2,375 KRW | -9,221.33 KRW |
| 2009 | 10,559.57 KRW | -198.43 KRW | -1,529.86 KRW |
| 2010 | 8,683.7 KRW | -512.4 KRW | -1,077 KRW |
| 2011 | 10,889.36 KRW | 334.91 KRW | 143.82 KRW |
| 2012 | 11,395.67 KRW | 268.17 KRW | -245.5 KRW |
| 2013 | 10,597.08 KRW | 149.08 KRW | 182.62 KRW |
| 2014 | 8,545 KRW | 12 KRW | -475.36 KRW |
| 2015 | 7,499.2 KRW | 138.47 KRW | 36.67 KRW |
| 2016 | 5,686.13 KRW | -27.13 KRW | -163.33 KRW |
| 2017 | 4,719.07 KRW | -342 KRW | -582.8 KRW |
| 2018 | 3,696.6 KRW | -422.55 KRW | -778.3 KRW |
| 2019 | 1,246.02 KRW | -153.48 KRW | -364.24 KRW |
| 2020 | 1,373.43 KRW | -285.73 KRW | -1,532.52 KRW |
| 2021 | 1,957.85 KRW | -78.02 KRW | -601.19 KRW |
| 2022 | 2,458.13 KRW | 35.17 KRW | -324.62 KRW |
| 2023 | 910.8 KRW | -200.65 KRW | -820.43 KRW |
WellBiotec Co business model
WellBiotec Co is one of the most popular companies on Eulerpool.com.
WellBiotec Co Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
WellBiotec Co historical P/E ratio, EBIT multiple, and P/S ratio
WellBiotec Co shares outstanding KR7010600005 ·
The number of shares was WellBiotec Co in 2023 — This indicates how many shares 79.197 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue WellBiotec Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates WellBiotec Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of WellBiotec Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating WellBiotec Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 2 M Aktien |
| 2005 | 2 M Aktien |
| 2006 | 3 M Aktien |
| 2007 | 2 M Aktien |
| 2008 | 3 M Aktien |
| 2009 | 7 M Aktien |
| 2010 | 10 M Aktien |
| 2011 | 11 M Aktien |
| 2012 | 12 M Aktien |
| 2013 | 13 M Aktien |
| 2014 | 14 M Aktien |
| 2015 | 15 M Aktien |
| 2016 | 15 M Aktien |
| 2017 | 15 M Aktien |
| 2018 | 20 M Aktien |
| 2019 | 42 M Aktien |
| 2020 | 44 M Aktien |
| 2021 | 55.36 M Aktien |
| 2022 | 64.32 M Aktien |
| 2023 | 79.2 M Aktien |
WellBiotec Co stock splits
In WellBiotec Co's history, there have been no stock splits.
WellBiotec Co dividend history and estimates KR7010600005 ·
In 2023, WellBiotec Co paid a dividend amounting to 0 KRW. Dividend means that WellBiotec Co distributes a portion of its profits to its owners.
3 years
5 years
10 years
25 Years
Max
Dividend
Dividend (Estimate)
Details
Dividend
ⓘDividend Overview
The dividend per year chart for WellBiotec Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
Interpretation and Use
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify WellBiotec Co’s potential for long-term investment and income generation through dividends.
Investment Strategy
Incorporate the dividend data in evaluating WellBiotec Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
WellBiotec Co Dividend History
| Date | WellBiotec Co Dividend |
|---|---|
| 2005 | 136.36 undefined |
| 2004 | 90.91 undefined |
| Dividend | Dividend (Estimate) | |
|---|---|---|
| 2004 | 90.91 KRW | 0 KRW |
| 2005 | 136.36 KRW | 0 KRW |
| 2006 | 0 KRW | 0 KRW |
| 2007 | 0 KRW | 0 KRW |
| 2008 | 0 KRW | 0 KRW |
| 2009 | 0 KRW | 0 KRW |
| 2010 | 0 KRW | 0 KRW |
| 2011 | 0 KRW | 0 KRW |
| 2012 | 0 KRW | 0 KRW |
| 2013 | 0 KRW | 0 KRW |
| 2014 | 0 KRW | 0 KRW |
| 2015 | 0 KRW | 0 KRW |
| 2016 | 0 KRW | 0 KRW |
| 2017 | 0 KRW | 0 KRW |
| 2018 | 0 KRW | 0 KRW |
| 2019 | 0 KRW | 0 KRW |
| 2020 | 0 KRW | 0 KRW |
| 2021 | 0 KRW | 0 KRW |
| 2022 | 0 KRW | 0 KRW |
| 2023 | 0 KRW | 0 KRW |
WellBiotec Co dividend payout ratio KR7010600005 ·
In 2023, WellBiotec Co had a payout ratio of 16.38%. The payout ratio indicates the percentage of the company's profits that WellBiotec Co distributes as dividends.
3 years
5 years
10 years
25 Years
Max
Payout ratio
Details
Payout ratio
ⓘWhat is Yearly Payout Ratio?
The yearly payout ratio for WellBiotec Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
How to Interpret the Data
A lower payout ratio for WellBiotec Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Using the Data for Investments
Evaluate WellBiotec Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
WellBiotec Co Payout Ratio History
| Date | WellBiotec Co Payout ratio |
|---|---|
| 2023 | 16.38 % |
| 2022 | 16.38 % |
| 2021 | 16.38 % |
| 2020 | 16.38 % |
| 2019 | 16.38 % |
| 2018 | 16.38 % |
| 2017 | 16.39 % |
| 2016 | 16.39 % |
| 2015 | 16.35 % |
| 2014 | 16.43 % |
| 2013 | 16.38 % |
| 2012 | 16.25 % |
| 2011 | 16.66 % |
| 2010 | 16.21 % |
| 2009 | 15.88 % |
| 2008 | 17.9 % |
| 2007 | 14.86 % |
| 2006 | 14.86 % |
| 2005 | 23.99 % |
| 2004 | 5.74 % |
| Payout ratio | |
|---|---|
| 2004 | 5.74 % |
| 2005 | 23.99 % |
| 2006 | 14.86 % |
| 2007 | 14.86 % |
| 2008 | 17.9 % |
| 2009 | 15.88 % |
| 2010 | 16.21 % |
| 2011 | 16.66 % |
| 2012 | 16.25 % |
| 2013 | 16.38 % |
| 2014 | 16.43 % |
| 2015 | 16.35 % |
| 2016 | 16.39 % |
| 2017 | 16.39 % |
| 2018 | 16.38 % |
| 2019 | 16.38 % |
| 2020 | 16.38 % |
| 2021 | 16.38 % |
| 2022 | 16.38 % |
| 2023 | 16.38 % |
Unfortunately, there are currently no price targets and forecasts available for WellBiotec Co.
WellBiotec Co shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 7.01111 % | Metafreeze Co., Ltd. | 6,374,502 | 0 | 3/31/2024 |
| 0.53113 % | NH Investment & Securities Co. Ltd. | 482,907 | -279,775 | 3/31/2024 |
| 0.47556 % | Dimensional Fund Advisors, L.P. | 432,378 | 0 | 8/31/2024 |
| 0.06010 % | State Street Global Advisors (US) | 54,639 | 0 | 9/30/2024 |
| 0.01209 % | Hanwha Asset Management Co., Ltd. | 10,988 | -437 | 5/31/2024 |
| 0.00711 % | Mirae Asset Global Investments Co., Ltd. | 6,466 | 427 | 12/31/2023 |
| 0.00541 % | Dimensional Fund Advisors, Ltd. | 4,923 | 0 | 8/31/2024 |
| 0.00010 % | Korea Investment Management Co., Ltd. | 90 | 0 | 3/31/2024 |
| 0 % | Kiwoom Asset Management Co., Ltd. | 0 | -32,456 | 1/31/2024 |
| 0 % | Samsung Asset Management Co., Ltd. | 0 | -10,960 | 7/31/2024 |
1
2
WellBiotec Co Supply Chain
| Name | Relationship | Two-week correlation | One-month correlation | Three-Month Correlation | Six-Month Correlation | One Year Correlation | Two-Year Correlation |
|---|---|---|---|---|---|---|---|
| SupplierCustomer | 0,28 | -0,51 | -0,14 | 0,04 | 0,28 | -0,12 | |
| SupplierCustomer | 0,27 | -0,14 | -0,43 | -0,55 | -0,19 | -0,15 | |
| SupplierCustomer | 0,17 | -0,58 | 0,12 | -0,05 | -0,56 | -0,46 | |
| SupplierCustomer | -0,46 | 0,74 | -0,17 | -0,07 | 0,75 | 0,69 | |
| SupplierCustomer | -0,68 | 0,74 | -0,29 | -0,52 | -0,17 | -0,04 | |
| SupplierCustomer | -0,90 | 0,45 | -0,39 | -0,60 | 0,58 | 0,31 |
1
Most common questions regarding WellBiotec Co
What is the P/S ratio of WellBiotec Co 2024?
The P/S cannot be calculated for WellBiotec Co currently.
What is the Quality Investing of WellBiotec Co?
The Quality Investing for WellBiotec Co is 4/10.
What is the revenue of WellBiotec Co 2024?
The revenue cannot currently be calculated for WellBiotec Co.
How high is the profit of WellBiotec Co 2024?
The profit cannot currently be calculated for WellBiotec Co.
What is the business model of WellBiotec Co
No history available for WellBiotec Co.
What is the WellBiotec Co dividend?
WellBiotec Co pays a dividend of 0 KRW distributed over payouts per year.
How often does WellBiotec Co pay dividends?
The dividend cannot currently be calculated for WellBiotec Co or the company does not pay out a dividend.
What is the WellBiotec Co ISIN?
The ISIN of WellBiotec Co is KR7010600005.
What is the WellBiotec Co ticker?
The ticker of WellBiotec Co is 010600.KS.
How much dividend does WellBiotec Co pay?
Over the past 12 months, WellBiotec Co paid a dividend of 136.36 KRW . This corresponds to a dividend yield of about 25.02 %. For the coming 12 months, WellBiotec Co is expected to pay a dividend of 0 KRW.
What is the dividend yield of WellBiotec Co?
The current dividend yield of WellBiotec Co is 25.02 %.
When does WellBiotec Co pay dividends?
WellBiotec Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.
How secure is the dividend of WellBiotec Co?
WellBiotec Co paid dividends every year for the past 0 years.
What is the dividend of WellBiotec Co?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is WellBiotec Co located?
WellBiotec Co is assigned to the 'Cyclical consumption' sector.
Wann musste ich die Aktien von WellBiotec Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of WellBiotec Co from 4/24/2006 amounting to 150 KRW, you needed to have the stock in your portfolio before the ex-date on 12/28/2005.
When did WellBiotec Co pay the last dividend?
The last dividend was paid out on 4/24/2006.
What was the dividend of WellBiotec Co in the year 2023?
In the year 2023, WellBiotec Co distributed 0 KRW as dividends.
In which currency does WellBiotec Co pay out the dividend?
The dividends of WellBiotec Co are distributed in KRW.
WellBiotec Co stock
Sector
Cyclical consumption
Industry
Textiles
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website WellBiotec Co
Country
South Korea 🇰🇷
Currency
KRW
Initial public offering
Jul 18, 1997
GOSIN
Global Open Securities Identification Number
Cusip
Y9854U104
Market capitalization
Quality Investing
4 / 10Details
PEG
0
P/E ratio
Forward P/E ratio
0
P/S ratio
Forward P/S ratio
0
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
WellBiotec Co Peer Group
WellBiotec Co Eulerpool News
WellBiotec Co News
WellBiotec Co FIGI
| WellBiotec Co Ticker | WellBiotec Co FIGI |
|---|---|
| 010600:KS | BBG000BRH8L8 |
| 010600:KP | BBG000BRH981 |
All fundamentals about WellBiotec Co
Our stock analysis for WellBiotec Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of WellBiotec Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- WellBiotec Co Revenue
- WellBiotec Co Net Income
- WellBiotec Co P/E
- WellBiotec Co P/S
- WellBiotec Co EBIT
- WellBiotec Co Dividend
- WellBiotec Co Stocks
- WellBiotec Co Market capitalization
- WellBiotec Co Debt
- WellBiotec Co Liabilities
- WellBiotec Co Equity
- WellBiotec Co AAQS
- WellBiotec Co Employees
- WellBiotec Co ROE
- WellBiotec Co ROA
- WellBiotec Co ROCE